IN REPLY: We thank Dr Vordermark for his comments on our recent publication regarding health-related quality of life (QoL) in oligodendroglioma patients treated with either radiation therapy or radiation with adjuvant chemotherapy.
Based on the health-related QoL data from this study, as well as the randomized study in glioblastoma patients, we have recently completed a validation study of the European Organisation for Research and Treatment of Cancer (EORTC) Brain Cancer Module. The results have been submitted for presentation during the upcoming American Society of Clinical Oncology meeting, and an article on this issue is currently being written. Also, the EORTC will publish these data, together with data from other disease sites, in the EORTC reference values manual.
With this information we hope to accomodate Dr Vordermark’s request, and we wish to share our data with other research groups.